Pfizer/BioNTech requests FDA authorization to allow COVID vaccines for children under 5

The COVID-19 vaccine gold rush for big pharmaceutical companies isn’t quite yet over, as evidenced this week after reports surfaced that Pfizer and BioNTech have filed “emergency use authorization” applications to the Food and Drug Administration (FDA) to allow vaccines for children under the age of 5. 

According to the Washington Examiner, it appears as though the big pharma leader in COVID vaccinations will be granted the authorization, with some speculating that it could come by the end of February.

Notably — and downright eye-opening — the Examiner revealed in an earlier report that the Pfizer vaccine failed to produce a proper immune response in children of that age group, but apparently following the profit is of a much higher priority than following the science.

Pfizer CEO Albert Bourla, presumably knowing he’d be hammered on such a request, quickly released a statement in an attempt to justify use of the vaccines in such young children.

“As hospitalizations of children under 5 due to COVID-19 have soared, our mutual goal with the FDA is to prepare for future variant surges and provide parents with an option to help protect their children from this virus,” Bourla said.

He added: “Ultimately, we believe that three doses of the vaccine will be needed for children 6 months through 4 years of age to achieve high levels of protection.”

In other words, if one vaccination isn’t adequate, pump their young bodies full of multiple doses.

As it stands, children as young as 5 can receive a vaccine series, but boosters are only authorized for children at least 16 years old.